Literature DB >> 25323306

Effect of microRNA-21 on multidrug resistance reversal in A549/DDP human lung cancer cells.

Zuoliang Dong1, Li Ren2, Li Lin3, Jiang Li1, Yiwen Huang1, Jinhong Li1.   

Abstract

Lung cancer is a predominant cause of cancer-related mortality and numerous lung cancer patients succumb to the disease due to drug resistance. A number of microRNAs (miRNAs) are upregulated in cancer and are involved in tumorigenesis, functioning as oncogenes. Several functional studies have shown that miR-21 is important in carcinogenesis; however, none of these studies has investigated multidrug resistance (MDR) reversal in human lung cancer cells. In the present study, the effect of miR-21 on MDR reversal was analyzed in A549/DDP lung cancer cells. The data demonstrated the following after miR-21 silencing: Proliferation of the tumor cells was inhibited, cell apoptosis and oxidative damage were increased, the cell cycle was blocked at the G0/G1 phase, expression levels of P-glycoprotein were reduced, accumulation of Rhodamine 123 was increased, and the MDR-related genes encoding MDR1, MPR, glutathione S-transferase-π, B-cell lymphoma 2, cyclin-dependent kinase 1, cystathione and glutathione were downregulated. Further mechanistic analysis revealed that miR-21 silencing reduced AKT phosphorylation and transcriptional activation of E2F-1 and Twist. In conclusion, this study demonstrated that miR-21 silencing reversed lung cancer cell MDR by modulation of MDR-related gene expression and inhibition of the AKT signaling pathway, suggesting that miR-21 may be a potential therapeutic candidate in patients with MDR lung cancer.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25323306     DOI: 10.3892/mmr.2014.2662

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  19 in total

Review 1.  MicroRNA Pharmacoepigenetics: Posttranscriptional Regulation Mechanisms behind Variable Drug Disposition and Strategy to Develop More Effective Therapy.

Authors:  Ai-Ming Yu; Ye Tian; Mei-Juan Tu; Pui Yan Ho; Joseph L Jilek
Journal:  Drug Metab Dispos       Date:  2015-11-13       Impact factor: 3.922

2.  MiR-285 targets P450 (CYP6N23) to regulate pyrethroid resistance in Culex pipiens pallens.

Authors:  Mengmeng Tian; Bingqian Liu; Hongxia Hu; Xixi Li; Qin Guo; Feifei Zou; Xianmiao Liu; Mengxue Hu; Juxin Guo; Lei Ma; Dan Zhou; Yan Sun; Bo Shen; Changliang Zhu
Journal:  Parasitol Res       Date:  2016-09-20       Impact factor: 2.289

3.  Resistance to cancer chemotherapeutic drugs is determined by pivotal microRNA regulators.

Authors:  Marta Geretto; Alessandra Pulliero; Camillo Rosano; Dinara Zhabayeva; Rakhmet Bersimbaev; Alberto Izzotti
Journal:  Am J Cancer Res       Date:  2017-06-01       Impact factor: 6.166

4.  Evaluation of plasma microRNA levels to predict insensitivity of patients with advanced lung adenocarcinomas to pemetrexed and platinum.

Authors:  Jinghua Zhu; Yuhua Qi; Jianzhong Wu; Meiqi Shi; Jifeng Feng; Longbang Chen
Journal:  Oncol Lett       Date:  2016-10-19       Impact factor: 2.967

5.  Ultrasound-guided therapeutic modulation of hepatocellular carcinoma using complementary microRNAs.

Authors:  Sayan Mullick Chowdhury; Tzu-Yin Wang; Sunitha Bachawal; Rammohan Devulapally; Jung Woo Choe; Lotfi Abou Elkacem; Butrus Khuri Yakub; David S Wang; Lu Tian; Ramasamy Paulmurugan; Jürgen K Willmann
Journal:  J Control Release       Date:  2016-08-05       Impact factor: 9.776

Review 6.  The interplay between microRNAs and Twist1 transcription factor: a systematic review.

Authors:  Hashem Khanbabaei; Ali Teimoori; Milad Mohammadi
Journal:  Tumour Biol       Date:  2016-02-15

7.  LncRNA MEG3 enhances cisplatin sensitivity in non-small cell lung cancer by regulating miR-21-5p/SOX7 axis.

Authors:  Pei Wang; Dong Chen; Hongbing Ma; Yong Li
Journal:  Onco Targets Ther       Date:  2017-10-25       Impact factor: 4.147

Review 8.  Crosstalk between noncoding RNAs and ferroptosis: new dawn for overcoming cancer progression.

Authors:  Lei Zhang; Xiulan Zheng; Wen Cheng; Xuefei Zhang; Lingling Wang; Haixia Li
Journal:  Cell Death Dis       Date:  2020-07-24       Impact factor: 8.469

9.  Expression and significance of circulating microRNA-31 in lung cancer patients.

Authors:  Hai-Jun Yan; Ji-Yong Ma; Li Wang; Wei Gu
Journal:  Med Sci Monit       Date:  2015-03-09

Review 10.  MicroRNAs as regulators of cisplatin-resistance in non-small cell lung carcinomas.

Authors:  Irina Fadejeva; Horst Olschewski; Andelko Hrzenjak
Journal:  Oncotarget       Date:  2017-12-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.